For policymakers & clinicians
Neutropenia has NCCN and ASCO/IDSA guidance and approved growth factors. Treatment-related lymphopenia, which independently predicts death in solid tumors and blood cancers, is measured on every CBC and acted on almost nowhere. This page lays out the evidence, the gap, and three requests that use authority HHS already holds.
The evidence in brief
The association is old, consistent, and cuts across tumor type and treatment modality. In 802 patients with lymphoma, metastatic breast cancer and advanced sarcoma, baseline lymphopenia (<1,000/µL) was present in about a quarter and independently predicted shorter overall survival in all three (RR 1.46–1.8) (Ray-Coquard et al., Cancer Research 2009). In 1,051 patients starting chemotherapy, a day-1 lymphocyte count ≤700/µL tripled the hazard of early death (HR 3.1) (Ray-Coquard et al., BJC 2001).
Treatment-induced lymphopenia is at least as important as baseline. In 297 patients with glioma, pancreatic and lung cancer, 83% began chemoradiation with a normal count; the median fell 63% by two months, 43% reached grade 3–4, and that severe lymphopenia doubled the hazard of death (HR 2.1, 95% CI 1.54–2.78). The median count stayed below 1,000 for the entire year (Grossman et al., JNCCN 2015). Deaths were overwhelmingly from tumor progression, not infection (Grossman et al., CCR 2011).
Meta-analyses agree: pooled adjusted HR 1.65 for severe radiation-induced lymphopenia across 20 studies, 1.92 in pancreas and 1.63 in brain (Damen 2021); HR 2.33 in a pancreas-specific analysis (Venkatesulu 2022); HR 1.99 in 1,944 glioma patients (2021 meta-analysis).
The immunotherapy era sharpened the point. In 10,498 propensity-matched patients starting checkpoint inhibitors, baseline ALC below 1.5 × 10⁹/L meant 24-month survival of 27.9% versus 35.3% (HR 1.26); the authors recommend incorporating baseline ALC into routine risk assessment (Ismail et al., Cancers 2026). In 18,186 real-world patients, higher baseline lymphocyte count was independently associated with better survival (Goldschmidt et al., 2023).
The gap
The practical consequence. A patient can complete adjuvant chemotherapy, be declared disease-free, and carry a grade 2 lymphocyte count for years without any clinician being required to notice. That is Beth's chart, at 525, from September 2023 to January 2026. The number was on every panel she had drawn.
Regulatory status
Anktiva (nogapendekin alfa inbakicept-pmln, N-803) is an IL-15 receptor superagonist. Per its label it drives proliferation and activation of NK cells, CD8+ T cells and memory T cells without expanding regulatory T cells (approved label). Phase 1 data in solid tumors showed NK-cell expansion within a week of the first dose (Margolin et al., CCR 2018).
| Status | Indication | Basis |
|---|---|---|
| Approved | BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with BCG, intravesical. April 22, 2024. | 77 patients; CR 62% (95% CI 51–73); 58% of responses ≥12 months, 40% ≥24 months (FDA). Peer-reviewed cohort: CR 71%, median duration 26.6 months (Chamie et al., NEJM Evidence 2023). |
| Under review | Papillary-only BCG-unresponsive NMIBC (supplemental BLA). | Accepted; PDUFA date January 6, 2027 (ImmunityBio). |
| Not approved | Lymphopenia reversal in relapsed/refractory solid tumors (ALC <1,000/µL), subcutaneous. | RMAT designation; FDA Expanded Access authorization June 2025. Expanded access is not approval and does not establish efficacy (company release). |
| Not approved | Glioblastoma, NSCLC, pancreatic cancer, multiple myeloma, Long COVID. | Clinical trials only. Company-reported, non-randomized signals: pancreatic (QUILT-88) OS HR 0.46 in patients whose lymphopenia reversed, a responder analysis subject to immortal-time bias (ASCO 2025); recurrent GBM mean ALC 0.9 → ≥1.4 × 10³/µL within one cycle, p < 0.001 (QUILT-3.078). |
"The survival data for lymphopenia reversal are single-arm and company-reported."
Correct. They are hypothesis-generating, and the right response is a randomized trial with ALC recovery as a pre-specified endpoint, not a shrug. The prognostic literature above, by contrast, is independent, peer-reviewed and decades old.
"The FDA sent the sponsor a warning letter."
It did, on March 13, 2026, about promotional claims (FDA). That concerns marketing language, not the approved indication's safety or efficacy, and it is why this site cites the label and the literature rather than the advertising.
"Why should HHS care about one company's drug?"
It should not, and this site does not ask it to. The ALC is already on every cancer patient's CBC. Whether the intervention is Anktiva, another IL-15 agonist, or spleen-sparing radiotherapy planning, the policy question is the same: why is a validated predictor of survival not monitored, reported, or acted on?
The ask
1 · Measure
Ask NCI and CDC to convene NCCN and ASCO to add ALC monitoring, with a threshold for action, to supportive-care and survivorship guidance, alongside the existing neutropenia guidance (NCCN). The number is already on the panel; the cost of the ask is a paragraph.
2 · Expedite
The lymphopenia indication holds RMAT designation, which makes it eligible for priority review and accelerated approval (FDA guidance). Ask FDA to agree with the sponsor on a randomized, accelerated-approval pathway using lymphocyte recovery as an endpoint, and to prioritize the pending papillary supplement (FDA).
3 · Cover
Medicare can cover a therapy on condition that patients are enrolled in a registry or study, under Coverage with Evidence Development (CMS). Ask CMS to open a national coverage determination with CED for IL-15 therapy in treatment-related lymphopenia, tied to the existing expanded-access protocol. The registry would generate the controlled data everyone says is missing.
And meet them. Justin, Lisa, Valerie, Andrew, Alan and Beth are alive and willing to sit across a table. Thirty minutes with them will do more than any deck.
For the clinic, today
Every figure on this site was checked against the cited page. If you find an error, or a guideline we missed, write to us and we will fix it and say so.